Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4381058 | 0.91 | EPHX1 (0.33) | EPHX1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL4371149 | 0.88 | EPHX1 (0.35) | EPHX1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL4369916 | 0.88 | EPHX1 (0.36) | EPHX1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL4368160 | 0.87 | LMNA (0.36) | CYP3A4LMNAHRH1ALDH1A1TP53 | |
| SCHEMBL4369917 | 0.84 | HTT (0.36) | CYP3A4TSHRCYP2C19LMNACNR1 | |
| SCHEMBL4367983 | 0.84 | RIPK1 (0.38) | EPHX1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL4379961 | 0.83 | EPHX1 (0.36) | EPHX1TSHRLMNARAB9ANR1I2 | |
| SCHEMBL4366200 | 0.82 | EPHX1 (0.35) | EPHX1CYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL4379662 | 0.79 | RIPK1 (0.35) | EPHX1TSHRLMNARAB9ANR1I2 | |
| SCHEMBL4381943 | 0.79 | RIPK1 (0.35) | EPHX1TSHRLMNARAB9ANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2623509-A1 | Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex | Kanto Kagaku Kabushiki Kaisha (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | EPHX1 4308/4885CYP1A2 111/4885CYP3A4 68/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | EPHX1 3253/4885CYP1A2 643/4885CYP3A4 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.